ETC
ELVN icon

Exchange Traded Concepts’s Enliven Therapeutics ELVN Stock Holding History

Exchange Traded Concepts’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,055
Closed -$119K – 1433
2025
Q1 		$119K Sell
6,055
-1,428
-19% -$30.7K ﹤0.01% 1093
2024
Q4 		$168K Hold
7,483
– – ﹤0.01% 1028
2024
Q3 		$191K Sell
7,483
-11,350
-60% -$263K ﹤0.01% 983
2024
Q2 		$440K Sell
18,833
-5,858
-24% -$123K 0.01% 722
2024
Q1 		$434K Buy
24,691
+15,983
+184% +$245K 0.01% 668
2023
Q4 		$121K Buy
8,708
+2,208
+34% +$27K ﹤0.01% 865
2023
Q3 		$88.8K Sell
6,500
-434
-6% -$7.31K ﹤0.01% 944
2023
Q2 		$142K Buy
+6,934
New +$140K ﹤0.01% 859

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exchange Traded Concepts's ELVN Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 6,055 shares — an estimated $119K sold.

Exchange Traded Concepts first reported a position in ELVN in Q2 2023 and held it in 8 quarters. The position peaked at $440K in Q2 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 6,055 Enliven Therapeutics shares in Q2 2025, an estimated $119K.
  • Exchange Traded Concepts first reported a position in Enliven Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Enliven Therapeutics position peaked at $440K in Q2 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.